MUC5B and asthma: Recent evidence suggests mucin-specific approaches could be of benefit: complete MUC5B removal from the airway may be detrimental [61], whilst the identification of MUC5AC as an essential non-contractile mediator of AHR [62] and the role of MUC5AC in tethering [52] suggest MUC5AC-specific therapies could be of benefit in asthma.